Company Overview
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel, which is in preclinical trial phase for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -28.12% |
| 6 Months: | -28.12% |
| 3 Months: | -9.11% |
| 1 Month: | +5.44% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)57.20 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 54.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RNTX Rein Therapeutics Inc. PHARMA | 0.86 | -0.51 | $74.19M | 0.00% | -121.99% | -96.42% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 0 | 0 | - | 0 | 0 | 0 | - | 0 | 0 | 0 | - | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.61M | 6.87M | 5.49M | 3.96M | 5.23M |
| Operating Income | -3.94M | -5.55M | -4.23M | -4.45M | -4.59M | -4.95M | -6.43M | -7.04M | -7.76M | -9.66M | -7.50M | -6.98M | -7.31M | -7.38M | -7.92M | -7.35M | -6.88M | -4.40M | -5.03M | -4.19M | -6.99M | -6.01M | -6.79M | -8.42M | -8.04M | -6.48M | -5.01M | -1.99M | -1.98M | -7.21M | -9.04M | -6.07M | - | -5.61M | -6.87M | -5.49M | -3.96M | -5.23M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.61M | -6.87M | -5.49M | -3.96M | -5.23M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.50M | -6.82M | -5.58M | -32.68M | -5.84M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -3.92M | -5.53M | -4.22M | -4.44M | -4.56M | -4.92M | -6.26M | -6.87M | -7.59M | -9.49M | -7.43M | -7.03M | -7.21M | -7.17M | -7.75M | -7.24M | -6.75M | -4.39M | -5.02M | -4.93M | -6.97M | -5.69M | -6.70M | -8.42M | -7.99M | -6.37M | -4.78M | -1.79M | -1.83M | -7.11M | -8.94M | -5.85M | - | -5.50M | -6.82M | -5.58M | -31.97M | -5.84M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.06 | -0.07 | -1.86 | -1.76 | -1.40 | -1.05 | -0.39 | -0.40 | -0.86 | -0.45 | -0.27 | - | -0.25 | -0.28 | -0.21 | - | -0.19 |
| R&D Expense | 2.49M | 2.09M | 2.60M | 3.09M | 2.94M | 3.16M | 3.83M | 4.31M | 4.85M | 5.32M | 4.32M | 3.96M | 4.17M | 4.30M | 4.47M | 4.71M | 4.07M | 2.49M | 2.68M | 1.93M | 4.32M | 3.85M | 4.28M | 5.89M | 5.43M | 4.24M | 1.81M | 187.00K | 22.00K | 3.46M | 3.74M | 3.72M | - | 3.05M | 4.29M | 1.68M | - | 3.07M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | 27.65M | 15.35M | 28.11M | 21.93M |
| Operating Income | -12.89M | -18.17M | -23.01M | -31.90M | -29.96M | -20.50M | - | -27.65M | -15.35M | -28.11M | -21.93M |
| EBITDA | - | - | - | - | - | - | - | -27.48M | -15.23M | -28.05M | -21.93M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | -27.33M | -15.68M | -64.43M | -50.58M |
| Tax Provision | - | - | - | - | - | - | - | - | 0 | -1.54M | -712.00K |
| Net Income | -12.88M | -18.12M | -22.60M | -31.55M | -29.37M | -27.33M | - | -27.33M | -15.73M | -62.88M | -49.87M |
| Diluted EPS | - | - | - | - | - | - | - | -6.02 | -3.42 | -3.51 | -1.96 |
| R&D Expense | 7.83M | 10.28M | 14.24M | 18.45M | 17.66M | 11.17M | 17.01M | 17.97M | 3.99M | 14.25M | 11.03M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 22.02M | 52.69M | 30.31M | 26.47M | 16.34M | - | 22.01M | 106.01M | 62.19M | 24.16M |
| Current Assets | - | - | - | - | - | - | - | - | 21.87M | 18.27M | 13.66M | 4.33M |
| Cash & Equivalents | 6.21M | 3.77M | 20.71M | 11.86M | 10.63M | 5.31M | 7.05M | - | 5.19M | 17.31M | 12.87M | 3.21M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 4.08M | 4.89M | 10.71M | 10.43M | 4.18M | - | 3.38M | 99.12M | 52.80M | 52.24M |
| Current Liabilities | - | - | 4.07M | 4.89M | 5.37M | 5.84M | 3.96M | - | 3.38M | 4.38M | 5.75M | 6.18M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | 162.00K | 33.00K | 48.00K | 0 | - |
| Total Equity | -82.04M | -94.32M | -111.81M | 47.80M | 19.60M | 16.05M | 12.16M | - | 18.62M | 6.89M | 9.39M | -28.09M |
| Shares Outstanding | - | - | - | - | - | - | - | - | 4.54M | 4.89M | 21.67M | 27.55M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -20.53M | -27.93M | -26.47M | -20.48M | - | -24.86M | -19.81M | -22.29M | -19.36M |
| Investing Cash Flow | - | -38.91M | 24.69M | -2.81M | 6.41M | -35.92M | 26.46M | 16.20M | 0 | - |
| Financing Cash Flow | - | 50.59M | 2.52M | 23.96M | 15.80M | - | 0 | 15.79M | 17.82M | 9.76M |
| Capital Expenditure | -94.00K | -142.00K | -4.42M | -151.00K | -5.00K | -157.00K | - | - | - | - |
| Free Cash Flow | - | -20.67M | -32.35M | -26.62M | -20.48M | - | -24.86M | -19.81M | -22.29M | -19.36M |
| Net Change in Cash | - | - | - | - | - | - | 1.59M | 12.18M | -4.47M | -9.61M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 13.7% | 16.2% | -47.3% | -161.0% | -183.0% | -224.7% | - | -146.7% | -228.4% | -669.9% | 177.6% |
| ROCE % | - | -101.2% | -48.1% | -127.9% | -145.2% | -165.5% | - | -148.5% | -15.1% | -49.8% | -122.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Voss Capital, LP | 6.10% | 5.26M | $4.21M |
| 2 | Cable Car Capital, LP | 6.02% | 5.20M | $4.16M |
| 3 | Adar1 Capital Management, LLC | 5.22% | 4.50M | $3.60M |
| 4 | Vanguard Capital Management LLC | 3.92% | 3.38M | $2.70M |
| 5 | Bios Capital Management, LP | 3.46% | 2.98M | $2.39M |
| 6 | Ikarian Capital, LLC | 3.42% | 2.95M | $2.36M |
| 7 | Great Point Partners LLC | 2.98% | 2.58M | $2.06M |
| 8 | Citadel Advisors Llc | 2.83% | 2.44M | $1.95M |
| 9 | Velan Capital Investment Management LP | 1.97% | 1.70M | $1.36M |
| 10 | Senvest Management LLC | 1.43% | 1.23M | $984.72K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RNTX
Here's Why You Should Add RNTX Stock to Your Portfolio Now - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxPRXh2RVZDSlRyM3U2WDlvZzc2dUJobW9NMGJwNEhUS3F4N0ZmU25DRGlDUE1Gd2FyQjJBWEpOZ2Q4U3ZMWGcxQl9jYVV1WFc0RTJUU3h3TnhyZGppRVhvRjJyOUJFd0wwTjNaUjk3R0dPYkRudHZVWXpMTVVwSndCQXJXWWROZU5oV0Jodm…
A study of an inhaled treatment for lung scarring will be presented Sept. 8 in Barcelona. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOMFg5LWtKWHZWMzJPWndqMDRKSWp3Vmw2eGNiUUcyM1VlLTBuaWxWNkp0d2J2TEUzUmdOcGRVNk42RWdDRGN1cmVzSkNtdHRWckExY0MtbGxhWmV5blE2b2FUUTRPN1hoWnFJVTRNeDhUOXB5elgtcHU5ZF9PUUlkam8tUVVGZEpvSHRQbz…
We're Hopeful That Rein Therapeutics (NASDAQ:RNTX) Will Use Its Cash Wisely - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxQeTdVX29OZGZBQzdqYm5LV2pXZGlfdUxaTXJlU3pwUDRPZkk2Z3pHa3g4WlhhdjBLZFRPakQzeEZPN04yeDVVVFE1X0hXdTZHZXozOTFLZldUbWJZYnRXX1VlRVh0LWlia2IwRV80bzJ6dEJJcGdVRk01eUdOUWZiLUVhZjE3blBoWjVPX1…
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxOVE1LTUZYX2ZXSnRyUklLZnFkckFvYXNNLXhMejdXYjM2bElLbGhkcDZHeUd1dldGZHptdnFtODFMOFloRmEwTGdlWFFLVHR1SkMzd2pJVlU4cUc5Sk9WTjlCdkJYQkJaeVcwa08tR0dwTFU0di1zRUFCenViTmxzb3NGcHJSQnJtNUIxTm…
RNTX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFB3eGFDUUYyRHlGRzJqY2txR041N1FLNGhrUVQ0bzIyMzNIWHA5QmE0QWJzeTRrYm1PVldWRHpJNU5VNi1HZEE?oc=5" target="_blank">RNTX</a> <font color="#6f6f6f">Finviz</font>…
RNTX Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9GZkJMUDVyY0lwcFZ1eEQ1OXZlUmNCdWtMMWZpTFV0VEN5QTdiMXJjcjh0ZDN0TVMwLXNveHNqdEhNUGFwTUJCbk5vLUlQYWQ1ZXctMmxnQnpvd0wweldhQWlvRDkxbWNORVRfZ3VoWVMwQTNjVFNDY1VR?oc=5" target="_blank">RNT…
RNTX — Frequently Asked Questions
What is the current share price of Rein Therapeutics Inc. (RNTX)?
As of 2026-09-19 21:16 PDT, Rein Therapeutics Inc. (RNTX) trades at $0.86 on NasdaqCM. Its 52-week range is $0.71 to $1.88.
What is the market capitalisation of RNTX?
Rein Therapeutics Inc. (RNTX) has a market capitalisation of $74.19M on NasdaqCM.
What is the P/E ratio of RNTX?
RNTX trades at a trailing price-to-earnings (P/E) ratio of -0.51. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 6.72.
What is the return on equity (ROE) of RNTX?
RNTX has a return on equity (ROE) of -96.42%. Its return on capital employed (ROCE) is -121.99%.
Is RNTX a good stock to buy?
This page provides a data-driven analysis of Rein Therapeutics Inc. (RNTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.